Cybin Inc. CLXPF Archives - Page 3 of 5

FridayJun 11, 2021 9:00 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Sponsor Kernel Flow, Ketamine Feasibility Study

Feasibility study is designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics Cybin, Kernel working together to leverage proprietary Kernel Flow device for psychedelic-based studies and clinical trials Ketamine is a dissociative injected anesthetic that blocks sensory perception Cybin (NEO: CYBN) (OTCQB: CLXPF) has announced a key step forward in its focus on progressing psychedelic therapeutics. The company will be sponsoring a feasibility study of the Kernel Flow technology; the study is designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://ibn.fm/BW1Jn). “We still have much to learn about what is occurring in the brain during a psychedelic…

WednesdayJun 09, 2021 9:15 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files International Patent to Protect Potential Patient Coverage in 153 Countries

Cybin submits first-ever Patent Cooperation Treaty (“PCT”) filing By filing a single PCT application, the company simultaneously seeks protection for its proprietary drug treatments in a large number of countries Cybin filed the PCT application to provide broad international patent protection of key intellectual property Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, continues to focus on its goal to improve the lives of those suffering from mental illness by changing the expectation of treatment. As part of that mission, the company has filed an international patent application that would provide the potential to obtain patent…

TuesdayJun 08, 2021 10:59 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Develops New Treatment Model, Announces Co-Sponsorship of First-Ever Trial to Treat Frontline Clinicians

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has developed EMBARK, a transdiagnostic psychotherapy model, and will be co-sponsoring an upcoming trial designed for frontline clinicians experiencing COVID-related distress. Cybin announced that the randomized, placebo-controlled trial will evaluate psychedelic-assisted psychotherapy with psilocybin in the treatment of symptoms of depression, anxiety, burnout and post-traumatic stress among doctors, nurses and healthcare professionals on the frontlines of COVID-19. EMBARK is a groundbreaking psychotherapy model that integrates leading clinical approaches aimed at promoting supportive healing with psychedelic medicine. Cybin is collaborating with a University of Washington team, led by…

ThursdayJun 03, 2021 9:58 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Participate at Upcoming LD Micro Invitational XI

Cybin (NEO: CYBN) (OTCQB: CLXPF) CEO Doug Drysdale will be participating at the 2021 LD Micro Invitational XI. The invitational will be held Thursday, June 10. As part of his participation, Drysdale will be presenting a live webcast featuring Cybin, a biotechnology company focused on progressing psychedelic therapeutics. Drysdale’s presentation is scheduled to begin at 3:30 p.m. ET. Interested individuals can register to view the Cybin presentation via the webcast. To view the presentation, visit https://ibn.fm/ZExCT To view the full press release, visit https://ibn.fm/GUgy6 About Cybin Inc. Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics for mental…

TuesdayJun 01, 2021 11:23 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Sponsor Pioneering Study Designed to Expand Understanding of Psychedelic Pharmacotherapy

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced the sponsorship of Kernel’s feasibility study of its Kernel Flow technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. In January 2021, Cybin announced that it would be partnering with Kernel to leverage its proprietary Kernel Flow device for psychedelic-based studies and clinical trials. The first-of-its-kind Kernel Flow device uses quantitative neuroimaging technology that can measure brain activity in real time using a wearable helmet during psychedelic treatments. “We still have much to learn about what is occurring in the brain during a psychedelic…

FridayMay 28, 2021 10:48 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at Upcoming Jefferies Virtual Health Care Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its Chief Executive Officer Doug Drysdale will be presenting at the Jefferies Virtual Health Care Conference 2021. Drysdale’s presentation is scheduled to begin at 1:00 p.m. Eastern Time on Tuesday, June 1, 2021. Interested parties should visit https://ibn.fm/Dx6YF to register for the webcast. The presentation will be webcast live via the above link, and a replay will be available for 30 days following the event. To view the full press release, visit https://ibn.fm/C8Y6e About Cybin Inc. Cybin is a leading biotechnology company focused on…

WednesdayMay 26, 2021 10:23 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces PCT Filing, Bringing Potential to Obtain Patent Coverage in 153 Countries

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed an international patent application that further strengthens its psychedelic derivative drug development candidates across 153 global jurisdictions. Per the update, the application, governed by the Patent Cooperation Treaty (“PCT”), grants Cybin the right to file future national applications into treaty member jurisdictions, including important potential markets for the company. The PCT claims a library of psychedelic derivative drug development candidates. “Technologies gained by Cybin resulting from our strategic acquisition of Adelia Therapeutics, coupled with subsequent research initiatives from our experienced scientific…

WednesdayMay 26, 2021 9:00 am

Cybin Inc. (NEO: CYBN) Files Patent Designed to Bolster IP Psychedelic Molecule, Delivery Mechanism Portfolio

Company files 12th patent to strengthen proprietary IP program Cybin believes treatments can decrease costs, increase access to important therapeutics Patent provides wide range of benefits in Cybin’s four drug candidate program Cybin (NEO: CYBN) (OTCQB: CLXPF) has filed a new provisional patent application designed to strengthen the company’s ongoing drug candidate programs (https://ibn.fm/9V5sv). Cybin, a biotechnology company focused on progressing psychedelic therapeutics, is focused on expanding its four active drug programs targeting depression, addiction and other psychiatric conditions alongside its growing portfolio of 50+ proprietary psychedelic molecules. “By continuing to innovate in directions to enhance the patient experience and…

TuesdayMay 25, 2021 1:36 pm

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Expands Team to Add Deep Clinical, Commercial and Regulatory Expertise

Cybin (NEO: CYBN) (OTCQB: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently appointed Alexander Belser as its chief clinical officer and Aaron Bartlone to serve as chief operating officer. Belser and Bartlone bring a wealth of experience and will provide the company with added insight and expertise in the expansion of its development and clinical operations in the U.S. and Europe. A recent article quoted Cybin CEO Doug Drysdale as saying, “These appointments will serve to strengthen our development and clinical operations globally and solidify Cybin’s position within the industry. Alex and Aaron…

ThursdayMay 20, 2021 12:25 pm

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Strengthens IP Portfolio with 12th Patent Filing

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has filed a provisional patent application in support of its ongoing drug candidate programs. The patent is the 12th patent filed by the company. In the announcement, the company noted that the application discloses novel compositions anticipated to have improved pharmacokinetic profiles while retaining significant efficacy measures of the original molecules; the patent also discusses innovative methods of deploying the novel compositions with faster therapeutic onset of Cybin’s psychedelic tryptamine, while reducing psychedelic side effects and decreasing duration of the therapeutic effect thereof. In addition, the patent…

Site Search

Company Search

Tag: Cybin Inc. CLXPF